Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

@inproceedings{Samartzis2014LossOA,
  title={Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition},
  author={Eleftherios Pierre Samartzis and Katrin Gutsche and Konstantin Johannes Dedes and Daniel Fink and Manuel Stucki and Patrick Imesch},
  booktitle={Oncotarget},
  year={2014}
}
ARID1A mutations are observed in various tumors, including ovarian clear cell (OCCC) and endometrioid carcinomas, endometrial, and breast carcinomas. They commonly result in loss of ARID1A-protein expression and frequently co-occur with PI3K/AKT-pathway activating mechanisms. The aim of this study was to test the hypothesis as to whether PI3K/AKT-pathway activation is a critical mechanism in ARID1A-mutated tumors and if consequently ARID1A-deficient tumors show increased sensitivity to… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2013
View 6 Excerpts
Highly Influenced

SWI/SNF nucleosome remodellers and cancer

Nature Reviews Cancer • 2011
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…